No Evidence Found to Support Discontinuing ACEIs, ARBs in COVID-19
TUESDAY, Jan. 26, 2021 -- For patients taking angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) and hospitalized with mild-to-moderate COVID-19, there is no significant difference in the mean number of days alive and out of the hospital with discontinuation or continuation of these medications, according to a study published in the Jan. 19 issue of the Journal of the American Medical Association.
Renato D. Lopes, M.D., Ph.D., from the D'Or Institute for Research and Education in Rio de Janeiro, and colleagues examined the impact of discontinuation versus continuation of ACEIs or ARBs on the number of days alive and out of hospital through 30 days among 659 patients hospitalized with mild-to-moderate COVID-19. Of the patients, 334 and 325 discontinued and continued ACEIs or ARBs, respectively.
The researchers observed no significant between-group difference in the number of days alive and out of the hospital (mean, 21.9 versus 22.9 for the discontinuation versus continuation groups; mean ratio, 0.95; 95 percent confidence interval, 0.90 to 1.01). The discontinuation and continuation groups showed no statistically significant difference in regards to death (2.7 versus 2.8 percent; odds ratio, 0.97; 95 percent confidence interval, 0.38 to 2.52), cardiovascular death (0.6 versus 0.3 percent; odds ratio, 1.95; 95 percent confidence interval, 0.19 to 42.12), or COVID-19 progression (38.3 versus 32.3 percent; odds ratio, 1.30; 95 percent confidence interval, 0.95 to 1.80).
"These findings do not support routinely discontinuing ACEIs or ARBs among patients hospitalized with mild-to-moderate COVID-19 if there is an indication for treatment," the authors write.
Several authors disclosed financial ties to the pharmaceutical industry.
© 2021 HealthDay. All rights reserved.
Posted: January 2021
Further Support and Information on COVID-19
Read this next
TUESDAY, March 2, 2021 -- Individuals with previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection generate strong responses to one dose of the BNT162b2...
TUESDAY, March 2, 2021 -- Treatment with interleukin-6 receptor antagonists tocilizumab and sarilumab improves outcomes among critically ill patients with COVID-19 receiving organ...
TUESDAY, March 2, 2021 -- A moderate-to-high level of past physical activity (PA) is associated with a lower risk for instant and 28-day death in relation to myocardial infarction...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.